A policy of selective implantation of drug eluting stents, in a minority of lesions most likely to benefit, seems to be a rational way to employ this new and currently costly technology The RAVEL and ...

A study has found that sirolimus-coated balloons vs thin drug-eluting stents in in-stent restenosis show similar favorable clinical outcomes.

Novel drug-coated balloons (DCB) did not outshine standard treatment with second generation drug-eluting stents (DES ...

PRNewswire New Delhi [India]1 Translumina was incorporated in 2011 as a sales marketing company specialising in coronary ...

In PCI, a catheter is passed usually from the femoral artery in the groin up to the heart and into the small ... blockage after placement. These drug-eluting stents yield a marked reduction ...

Undergoing percutaneous coronary intervention (PCI) for narrowed arteries with a novel bioadaptor is at least as effective as ...

Among patients undergoing non-cardiac surgery more than 1 year after coronary drug-eluting ... to guide stent implantation during percutaneous coronary intervention (PCI) in heart disease patients ...

The DynamX Bioadaptor device was noninferior to DES for TLF overall, but a landmark analysis reveals a potential strength.

As of 2023, drug-eluting stents hold the largest market share due ... significantly drives the demand for coronary stents.

The vascular stents market is anticipated to grow from USD 11.4 billion in 2024 to USD 15.6 billion by 2029, with a CAGR of 6.5%. This growth ...